MYMarcus Young

Marcus Young

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marcus Young has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The ELIZA Effect

    by Marcus Young, Michele Gaca, Natasha Holmes

    Artificial Intelligence models can be informative; they can provide insight and accelerate scientific discovery. However, they can also hallucinate, reproduce biases from their training data, manufacture spurious associations, and they remain susceptible to malicious corruption. Critically, contemporary AI models lack the capacity to reliably and reproducibly distinguish such biased, malicious or counterfactual training data from legitimate data. Moreover, they do not have the capability to reliably validate their outputs. The curation of their training data and the validation of their outputs therefore remain the responsibility of their human operators.

  • Open Access

    Delirium in ICU and Macbeth’s dagger: author’s reply

    by Marcus Young, Katarzyna Kotfis, Rinaldo Bellomo

  • Open Access

    A target trial emulation of dexmedetomidine to treat agitation in the intensive care unit

    by Ary Serpa, Marcus Young, Atthaphong Phongphithakchai, Akinori Maeda, Yukiko Hikasa, Nuttapol Pattamin, Nuanprae Kitisin, Gehan Premaratne, Gabriel Chan, Joseph Furler, et al.

    Objective Agitation is a major problem in the intensive care unit. However, no treatment has clearly emerged as effective and safe. Using target trial emulation, we aimed to test the hypothesis that early intervention with dexmedetomidine would accelerate agitation resolution. Methods We read clinical notes in an electronic medical records system with natural language […] ABSTRACT Objective Agitation is a major problem in the intensive care unit. However, no treatment has clearly emerged as effective and safe. Using target trial emulation, we aimed to test the hypothesis that early intervention with dexmedetomidine would accelerate agitation resolution. Methods We read clinical notes in an electronic medical records system with natural language […]


  • Open Access

    Natural language processing diagnosed behavioural disturbance phenotypes in the intensive care unit: characteristics, prevalence, trajectory, treatment, and outcomes

    by Marcus Young, Natasha E. Holmes, Kartik Kishore, Sobia Amjad, Michele Gaca, Ary Serpa Neto, Michael C. Reade, Rinaldo Bellomo

    Background: Natural language processing (NLP) may help evaluate the characteristics, prevalence, trajectory, treatment, and outcomes of behavioural disturbance phenotypes in critically ill patients. Methods: We obtained electronic clinical notes, demographic information, outcomes, and treatment data from three medical-surgical ICUs. Using NLP, we screened for behavioural disturbance phenotypes based on words suggestive of an agitated state, a non-agitated state, or a combination of both. Results: We studied 2931 patients. Of these, 225 (7.7%) were NLP-Dx-BD positive for the agitated phenotype, 544 (18.6%) for the non-agitated phenotype and 667 (22.7%) for the combined phenotype. Patients with these phenotypes carried multiple clinical baseline differences. On time-dependent multivariable analysis to compensate for immortal time bias and after adjustment for key outcome predictors, agitated phenotype patients were more likely to receive antipsychotic medications (odds ratio [OR] 1.84, 1.35–2.51, p < 0.001) compared to non-agitated phenotype patients but not compared to combined phenotype patients (OR 1.27, 0.86–1.89, p = 0.229). Moreover, agitated phenotype patients were more likely to die than other phenotypes patients (OR 1.57, 1.10–2.25, p = 0.012 vs non-agitated phenotype; OR 4.61, 2.14–9.90, p < 0.001 vs. combined phenotype). This association was strongest in patients receiving mechanical ventilation when compared with the combined phenotype (OR 7.03, 2.07–23.79, p = 0.002). A similar increased risk was also seen for patients with the non-agitated phenotype compared with the combined phenotype (OR 6.10, 1.80–20.64, p = 0.004). Conclusions: NLP-Dx-BD screening enabled identification of three behavioural disturbance phenotypes with different characteristics, prevalence, trajectory, treatment, and outcome. Such phenotype identification appears relevant to prognostication and trial design. Graphical


  • The effect of age on clinical dose equivalency of fentanyl and morphine analgosedation in mechanically ventilated patients: Findings from the ANALGESIC trial

    by Andrew Casamento, Angajendra Ghosh, Ary Serpa Neto, Marcus Young, Mervin Lawrence, Christina Taplin, Glenn M. Eastwood, Rinaldo Bellomo


  • Confusion regarding the use of Natural Language Processing in ICU delirium assessment. Author’s reply

    by Marcus Young, Natasha Holmes, Kartik Kishore, Ary Serpa-Neto, Rinaldo Bellomo


  • A Phase II Cluster-Crossover Randomized Trial of Fentanyl versus Morphine for Analgosedation in Mechanically Ventilated Patients

    by Andrew J Casamento, Ary Serpa Neto, Marcus Young, Mervin Lawrence, Christina Taplin, Glenn M Eastwood, Angajendra Ghosh, Rinaldo Bellomo

    Rationale: The continuous infusion of fentanyl or morphine is often prescribed to assist with analgesia and sedation (analgosedation) during mechanical ventilation. Objectives: To compare the effect of fentanyl versus morphine on patient-centered outcomes in ventilated patients. Methods: We conducted a cluster-randomized, cluster-crossover trial between July 2019 and August 2020 in two adult ICUs. We compared two continuous infusion regimens (fentanyl versus morphine). One ICU was randomized to the fentanyl–morphine sequence and the other to the morphine–fentanyl sequence. The primary outcome was the number of ventilator-free days at Day 28. Secondary outcomes included, among others, duration of mechanical ventilation in survivors and ICU-free days at Day 28. Measurements and Main Results: Via cluster allocation, we randomized 737 patients. Of these, 56 were excluded because of the opt-out consent process, leaving 681 (344 to fentanyl and 337 to morphine) for primary analysis (median [interquartile range] age, 59 [44–69] years). Median ventilator-free days at Day 28 were 26.1 (20.7–27.3) in the fentanyl versus 25.3 (19.1–27.2) in the morphine group (median difference, 0.79 [95% confidence interval, 0.31 to 1.28], P = 0.001). ICU-free days were greater (P < 0.001) and length of stay in the ICU for survivors shorter (P < 0.001) in the fentanyl group. All other secondary outcomes were not statistically different by treatment group. Conclusions: Among adult patients requiring mechanical ventilation, compared with morphine, fentanyl infusion significantly increased the median number of ventilator-free days at Day 28. The choice of opioid infusion agent may affect clinical outcomes and requires further investigation.